Heat Biologics, Inc. (HTBX)
Stock Price:
$1.67 USD
-0.16 (-8.74%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
248.10M |
| Revenue (ttm) |
3.50M |
| Net Income (ttm) |
-20.28M |
| Shares Out |
148.56M |
| EPS (ttm) |
-0.38 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$1.67 |
| Previous Close |
$1.83 |
| Change ($) |
-0.16 |
| Change (%) |
-8.74% |
| Day's Open |
1.72 |
| Day's Range |
1.63 - 1.73 |
| Day's Volume |
12,587,140 |
| 52-Week Range |
0.20 - 4.30 |
More Stats
| Market Cap |
248.10M |
| Enterprise Value |
202.95M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
148.56M |
| Float |
143.74M |
| EPS (basic) |
-0.44 |
| EPS (diluted) |
-0.38 |
| FCF / Share |
-0.17 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.58M |
| Short Ratio |
0.20 |
| Short % of Float |
9.54% |
| Beta |
0.82 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
70.87 |
| PB Ratio |
10.47 |
| Revenue |
3.50M |
| Operating Income |
-18.52M |
| Net Income |
-20.28M |
| Free Cash Flow |
-14.99M |
| Net Cash |
45.15M |
| Net Cash / Share |
0.30 |
| Gross Margin |
-284.65% |
| Operating Margin |
-529.11% |
| Profit Margin |
-579.30% |
| FCF Margin |
-428.34% |
| ROA |
-25.30% |
| ROE |
-59.43% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.38*
(162.28% upside)
Low
2.50
Current: $1.67
High
5.00
Target: 4.38
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 3.05 | 5.79 | 1.52 | 0.34 | - | - | - | - |
| Revenue Growth | -47.37% | 281.19% | 344.89% | - | - | - | - | - |
| Gross Profit | 3.05 | 5.79 | 1.52 | 0.34 | - | - | - | - |
| Operating Income | -20.13 | -17.46 | -13.12 | -13.13 | -21.02 | -12.19 | -6.56 | -2.35 |
| Net Income | -20.02 | -15.73 | -11.84 | -12.57 | -20.30 | -11.79 | -6.41 | -2.42 |
| Shares Outstanding | 33.28 | 17.49 | 3.85 | 1.76 | 0.80 | 0.65 | 0.37 | 0.18 |
| Earnings Per Share | -0.60 | -0.90 | -3.08 | -7.15 | -25.30 | -18.30 | -24.20 | -13.20 |
| Operating Cash Flow | -12.84 | -21.71 | -6.40 | -13.52 | -17.45 | -9.83 | -6.39 | -2.07 |
| Capital Expenditures | -0.16 | -0.59 | -0.06 | -0.05 | -0.12 | -0.46 | -0.05 | - |
| Free Cash Flow | -12.99 | -22.31 | -6.46 | -13.57 | -17.56 | -10.29 | -6.44 | -2.08 |
| Cash & Equivalents | 15.15 | 28.08 | 9.84 | 8.01 | 11.80 | 14.53 | 21.87 | 0.04 |
| Total Debt | 1.93 | - | - | - | 6.75 | 2.71 | - | 0.92 |
| Net Cash / Debt | 13.22 | 28.08 | 9.84 | 8.01 | 5.05 | 11.82 | 21.87 | -0.88 |
| Assets | 25.96 | 37.76 | 20.19 | 8.90 | 13.22 | 15.92 | 23.02 | 0.15 |
| Liabilities | 12.80 | 7.52 | 14.41 | 2.06 | 10.72 | 4.88 | 1.30 | 1.66 |
| Book Value | 13.57 | 30.29 | 7.37 | 8.80 | 4.05 | 11.76 | 21.99 | -1.52 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Heat Biologics, Inc. |
| Country |
United States |
| Employees |
36 |
| CEO |
Jeff A. Wolf |
Stock Information
| Ticker Symbol |
HTBX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: HTBX |
| IPO Date |
July 24, 2013 |
Description
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.